Evidence map›Paper›PMID 41620440›Full record

ArticleNature communications2026

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.

Zev A Wainberg, Jason M Link, Alykhan Premji, Serena Zheng, Michael Srienc, McKensie Hammons, Shineui E Kim, Luyi Li, Zeyu Liu, Olga Tsvetkova and 17 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03970252 (A Pilot and Feasibility Study of PD-1 Blockade With Nivolumab in Combination With Chemotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03970252 early_phase1completednot on this map

A Pilot and Feasibility Study of PD-1 Blockade With Nivolumab in Combination With Chemotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2019 to 2024Enrolled28ConditionsBorderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal AdenocarcinomaArmsFluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Zev A Wainberg *Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu.ORCID 0000-0002-7142-1246
Jason M Link *Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. jmlink@mednet.ucla.edu.ORCID 0000-0002-6892-0431
Alykhan PremjiDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Serena ZhengDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-3666-0513
Michael SriencDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0009-0009-0485-4154
McKensie HammonsDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Shineui E KimDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Luyi LiDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Zeyu LiuDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Olga TsvetkovaDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Evan R AbtJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Lee RosenDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Stephen KimDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Jonathan KingDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
O Joe HinesJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Mark GirgisJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Saeed SadeghiDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Olga OlevskyDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Deborah WongDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Lisa YonemotoDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Ann Marie SineyDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Kim KellyJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Christine KivorkJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Chi-Hong TsengDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-2549-6167
Caius G RaduJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-9338-5397
David W DawsonJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Timothy R DonahueJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.ORCID 0000-0002-1175-2545

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic CancerR01CA250529 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, RADU, CAIUS GABRIEL · 2021 to 2025
$3.1M
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancerR01CA260678 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, RADU, CAIUS GABRIEL · 2021 to 2025
$3.0M
UCLA Surgeon-Scientist Basic Cancer Research Training Program (UCLA Surgeon-Scientist BCRTP)T32CA302559 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vatche Agopian, MANUEL L PENICHET · 2025 to 2026
$544k
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA250529NCI NIH HHS R01 CA260678NCI NIH HHS T32 CA302559U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) RO1CA250529
6 · The paper itself

Abstract

Chemotherapy and immune checkpoint inhibitor combinations have failed to improve survival in pancreatic ductal adenocarcinoma (PDAC), except in rare microsatellite instability-high cases; most studies focused on advanced disease. Here, we present clinical and translational results from a single-arm, prospective phase 1b/2 investigator-initiated study (NCT03970252) evaluating neoadjuvant modified FOLFIRINOX (mFFX) plus nivolumab in patients with borderline-resectable PDAC. The co-primary endpoints of safety and pathological response rate were met, with 22 (79%) of 28 patients proceeding to surgery and no grade ≥3 immune-related adverse events. All grade 3-4 treatment-related adverse events were chemotherapy-related. By CAP scoring, 9% of patients achieved a complete pathologic response, 9% a near-complete response, and 72% a partial response. Secondary endpoints included CA 19-9 response rate, R0 resection rate, objective response rate, and disease-free survival (median 19.7 months, 95% CI: 7.3-30.8). In post-hoc analyses, median progression-free survival was 26 months (95% CI: 14.7-34.3), and median overall survival was 38 months (95% CI: 27.9-not reached). Exploratory gene expression, immunohistochemistry and spatial transcriptomics showed increased intratumoral plasma cells and CD8 T cells in treated patients versus mFFX-only controls, and lymphoid aggregates with high plasma-cell-to-B cell ratios enriched for terminally exhausted CD8 T cells with fewer progenitor exhausted CD8 T cells and central memory CD4 T cells.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalNeoadjuvant TherapyNivolumabPancreatic NeoplasmsAgedFemaleFluorouracilHumansIrinotecanLeucovorinMaleMiddle AgedOxaliplatinPathologic Complete ResponsePilot ProjectsFluorouracilfolfirinoxIrinotecanLeucovorinNivolumabOxaliplatin

Identifiers

PMID41620440
PMCPMC12963377

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.